KR20010018722A - Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof - Google Patents

Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof Download PDF

Info

Publication number
KR20010018722A
KR20010018722A KR1019990034793A KR19990034793A KR20010018722A KR 20010018722 A KR20010018722 A KR 20010018722A KR 1019990034793 A KR1019990034793 A KR 1019990034793A KR 19990034793 A KR19990034793 A KR 19990034793A KR 20010018722 A KR20010018722 A KR 20010018722A
Authority
KR
South Korea
Prior art keywords
formula
methyl
ethyl
compound
piperazinyl
Prior art date
Application number
KR1019990034793A
Other languages
Korean (ko)
Other versions
KR100494881B1 (en
Inventor
이병석
신상훈
Original Assignee
류덕희
경동제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 류덕희, 경동제약 주식회사 filed Critical 류덕희
Priority to KR10-1999-0034793A priority Critical patent/KR100494881B1/en
Publication of KR20010018722A publication Critical patent/KR20010018722A/en
Application granted granted Critical
Publication of KR100494881B1 publication Critical patent/KR100494881B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: Provided is a method for manufacturing ethyl 2-£2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)|benzoyl-3(S)-(1-hydroxyprophy-2-nilamino) acrylate more easily in a high yield. The compound is used in manufacturing an antibacterial agent, Levofloxacin, as an intermediate. CONSTITUTION: Ethyl 2-£2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)|benzoyl-3(S)-(1-hydroxyprophy-2-nilamino) acrylate represented by the formula (1) is manufactured by the following steps of: i) reacting ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoyl acetate of the formula (2) with triethyl orthoformate of the formula (3) under a nonpolar solvent at 20-200 deg.C, preferably 100-120 deg.C, for 2-50 hours, preferably 22-28 hours, to obtain an intermediate of the formula (4); and ii) reacting the intermediate of the formula (4) with (S)-(+)-2-amino-1-propanol having optical activity under a polar solvent at 0-100 deg.C, preferably 10-30 deg.C, for1-10 hours, preferably 2-3 hours, to obtain ethyl 2-£2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)|benzoyl-3(S)-(1-hydroxyprophy-2-nilamino) acrylate.

Description

에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 그의 제조방법 {Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof}Ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy-2-ylamino) acrylate and Method for preparing the same {Ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoylacetate and a process for preparing persons}

본 발명은 활성 항균제로서 유용한 약제의 제조시에 중간체로 사용될 수 있는 하기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 그의 제조방법에 관한 것이다.The present invention is ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl of the formula (1) which can be used as an intermediate in the preparation of a medicament useful as an active antimicrobial agent. -3 (S)-(1-hydroxypropy-2-ylamino) acrylate and a method for producing the same.

상기 화학식 1의 화합물은 광학활성을 갖는 화합물로서, 이 화합물의 라세미체를 제조하는 방법은 한국특허 공개공보 제92-12087호에 개시되어 있다.The compound of Formula 1 is a compound having optical activity, and a method for preparing a racemate of the compound is disclosed in Korean Patent Publication No. 92-12087.

상기 기술에 따르면, 하기 화학식 2의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트를 화학식 12의 디메틸포름아미드 디메틸아세탈 및 라세미체인 화학식 14의 2-아미노-1-프로판올과 반응시켜 화학식 15의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3-(1-히드록시프로피-2-닐아미노)아크릴레이트를 얻을 수 있다.According to the above technique, the ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate of formula (2) is a dimethylformamide dimethylacetal and racemate of formula (12) Is reacted with 2-amino-1-propanol of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3- (1-hydride) Roxypropy-2-ylamino) acrylate can be obtained.

그러나 상기 반응식 1의 제조방법은 출발물질인 화학식 12의 화합물이 고가이며 수분에 매우 민감하고 톨루엔등 인화성이 강한 용매를 사용하여 반응시키므로 산업적으로 적용하기에 부적절하다는 문제점이 있다.However, the preparation method of Scheme 1 has a problem that the compound of Formula 12, which is a starting material, is expensive and very sensitive to moisture, and reacts with a highly flammable solvent such as toluene, which is inappropriate for industrial application.

본 발명자들은 상기 문제점을 해결하기 위하여 많은 연구와 노력을 한 결과, 보다 간편하고 수득율이 높은 새로운 물질 및 그의 제조방법을 발견하게 되어 본 발명을 완성하였다.The present inventors have made a lot of research and efforts to solve the above problems, and as a result, have found a new material and a method for preparing the same, which is simpler and higher in yield.

본 발명의 목적은 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 그의 제조방법을 제공하는 것이다.An object of the present invention is ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropyn-2-yl Amino) acrylate and its manufacturing method are provided.

본 발명은 하기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트 및 이를 제조하는 방법에 관한 것이다.The present invention provides ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy-2) -Nylamino) acrylate and a method for preparing the same.

상기 화학식 1의 화합물의 제조방법을 하기 반응식 2를 들어 설명하면 다음과 같다.The preparation method of the compound of Formula 1 will be described with reference to Scheme 2 below.

상기 반응식 2에서, 상기 화학식 2의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 시판중인 상기 화학식 3의 트리에틸 올소포르메이트를 비극성용매하에 반응온도 20~200℃, 바람직하게는 100~120℃에서 2~50시간, 바람직하게는 22~28시간동안 반응시켜 중간체인 상기 화학식 4의 화합물을 제조하고, 이를 광학활성을 갖는 상기 화학식 5의 (S)-(+)-2-아미노-1-프로판올과 극성용매하에 반응온도 0~100℃, 바람직하게는 10~30℃에서 1~10시간, 바람직하게는 2~3시간 반응시켜 목적화합물을 정량적인 높은 수율로 간단하게 제조할 수 있다.In Scheme 2, a non-polar solvent is substituted with ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate of Formula 2 and commercially available triethyl olsoformate of Formula 3 Under the reaction temperature of 20 ~ 200 ℃, preferably 100 ~ 120 ℃ 2 to 50 hours, preferably 22 to 28 hours to prepare a compound of formula (4) as an intermediate, the formula 5 having an optical activity Under reaction of (S)-(+)-2-amino-1-propanol with polar solvent at a reaction temperature of 0 to 100 캜, preferably 10 to 30 캜 for 1 to 10 hours, preferably 2 to 3 hours. Compounds can be prepared simply in quantitative high yields.

한편 상기 화학식 2의 화합물을 비극성용매하에 트리에틸 올소프로메이트와 반응시켜 상기 화학식 4의 화합물을 얻은 후, 이를 분리하지 않고 비극성용매만을 감압제거한 다음 상기 화학식 5의 화합물과 극성용매하에 반응시켜 목적화합물을 얻는 것도 가능하다.Meanwhile, the compound of Formula 2 is reacted with triethyl olsopromate under a non-polar solvent to obtain the compound of Formula 4, and then only the non-polar solvent is removed under reduced pressure without separation, followed by reaction with the compound of Formula 5 under a polar solvent. It is also possible to obtain.

상기 방법에서 사용되는 비극성용매는 톨루엔, 벤젠 및 헥산 등으로 이루어진 군으로부터 선택되는 용매 또는 이들을 2종 이상 혼합하여 얻어지는 혼합용매를 예로 들 수 있다.Examples of the nonpolar solvent used in the above method include a solvent selected from the group consisting of toluene, benzene and hexane, or a mixed solvent obtained by mixing two or more thereof.

상기 방법에서 사용되는 극성용매는 디메틸술폭시드, 디메틸포름아미드, 디메틸아세트아미드, 아세토니트릴, 물 및 에탄올성용매 등으로 이루어진 군으로부터 선택되는 용매 또는 이들을 2종 이상 혼합하여 얻어지는 혼합용매를 예로 들 수 있다.Examples of the polar solvent used in the above method include a solvent selected from the group consisting of dimethyl sulfoxide, dimethylformamide, dimethylacetamide, acetonitrile, water and ethanol solvent, or a mixed solvent obtained by mixing two or more thereof. have.

상기 반응식 2에서, 출발물질로 사용되는 화학식 2의 화합물은 공지의 화합물[참조: Chem. Pharm. Bull., Vol. 34, 4098∼4102 (1986)]로서 하기 반응식 3과 같이 하기 화학식 6의 테트라플루오로벤조일클로라이드로부터 간단히 제조할 수 있다.In Scheme 2, the compound of Formula 2 used as a starting material is a known compound [see Chem. Pharm. Bull., Vol. 34, 4098-4102 (1986)] can be prepared simply from tetrafluorobenzoyl chloride represented by the following formula (6).

또한 상기 반응식 2에서, 광학활성을 갖는 화학식 5의 화합물은 하기 반응식 4와 같이 저렴한 화학식 10의 L-알라닌(L-Alanine)을 환원제를 사용하여 환원시킴으로써 천연으로부터 쉽게 얻을 수 있다.In addition, in Scheme 2, the compound of Formula 5 having optical activity can be easily obtained from nature by reducing L-Alanine of Formula 10, which is inexpensive as in Scheme 4, using a reducing agent.

상기 방법에서 사용되는 환원제는 수소화알루미늄리튬, 삼플루오로붕소, 라니니켈 또는 수소화붕소나트륨 등을 예로 들 수 있다.Reducing agents used in the above method may include lithium aluminum hydride, boron trifluoro, ranickel or sodium borohydride.

상기와 같이 본 발명의 방법으로 제조된 상기 화학식 1의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트는 항균제로 유용한 약제인 하기 화학식 11의 (-)-9-플루오로-2,3-디히드로-3(S)-메틸-10-(4-메틸-1-피페라지닐)-7-옥소-7H-피리도[1,2,3-데]-1,4-벤즈옥사진-6-카르복실산(레보플록사신; Levofloxacin)의 제조시 중간체로 사용할 수 있다.As described above, ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-( 1-hydroxypropy-2-ylamino) acrylate is a (-)-9-fluoro-2,3-dihydro-3 (S) -methyl-10- (4) -Methyl-1-piperazinyl) -7-oxo-7H-pyrido [1,2,3-de] -1,4-benzoxazine-6-carboxylic acid (levofloxacin; Levofloxacin) Can be used as

하기 실시예를 들어 본 발명을 보다 구체적으로 설명하지만, 이들이 본 발명을 제한하는 것은 아니다.The present invention is explained in more detail with reference to the following examples, but these are not limitative of the present invention.

실시예 1 : (S)-(+)-2-아미노-1-프로판올의 제조Example 1: Preparation of (S)-(+)-2-amino-1-propanol

75.9g(2mole)의 수소화알루미늄리튬을 100ml의 테트라히드로푸란에 혼탁시킨 용액을 0℃까지 냉각하고 89.1g(1mole)의 L-알라닌을 서서히 적가한 다음 60℃까지 가열하여 24시간동안 격렬하게 교반시켰다. 반응이 완결되면 0℃까지 냉각하고 360ml의 물 및 90ml의 15% 수산화나트륨수용액을 순차적으로 가하여 맹렬히 교반 후 침전물을 여과하여 제거한다. 이 반응 혼합액을 황산 마그네슘으로 건조하고 감압증류하여 테트라히드로푸란을 제거시켜 61.6g(82%)의 (S)-(+)-2-아미노-1-프로판올을 얻었다.A solution of 75.9 g (2 mole) of lithium aluminum hydride suspended in 100 ml of tetrahydrofuran was cooled to 0 ° C., 89.1 g (1 mole) of L-alanine was slowly added dropwise, and then heated to 60 ° C. and vigorously stirred for 24 hours. I was. After the reaction was completed, the mixture was cooled to 0 ° C., and 360 ml of water and 90 ml of 15% sodium hydroxide solution were sequentially added thereto, followed by vigorous stirring to remove the precipitate by filtration. The reaction mixture was dried over magnesium sulfate and distilled under reduced pressure to remove tetrahydrofuran to give 61.6 g (82%) of (S)-(+)-2-amino-1-propanol.

IR: υmax(cm-1): 3,345, 3,307, 3,160, 1,621, 1,593IR: υ max (cm -1 ): 3,345, 3,307, 3,160, 1,621, 1,593

H1NMR(CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):

1.03 (3H, d, =CHCH3), 2.79 (1H, m, -OH),1.03 (3H, d, = CHCH 3 ), 2.79 (1H, m, -OH),

2.98 (1H, m, =CHCH3), 3.23 (2H, t, -NH2),2.98 (1H, m, = CHCH 3 ), 3.23 (2H, t, -NH 2 ),

3.51 (2H, d, -CH2OH)3.51 (2H, d, -CH 2 OH)

[α]D= +18°(c=1.8, H2O)[α] D = + 18 ° (c = 1.8, H 2 O)

실시예 2: 에틸 2,3,4,5-테트라플루오로벤조일아세테이트의 제조Example 2: Preparation of ethyl 2,3,4,5-tetrafluorobenzoyl acetate

357.4g(2.1mole)의 디에틸말로네이트 칼륨염, 238.1g(2.5mole)의 마그네슘클로라이드와 222.6g(2.2mole)의 트리에틸아민을 5,000ml의 아세토니트릴에 혼탁시킨 용액을 10℃까지 냉각하여 2시간 교반하고, 여기에 212.6g(1mole)의 테트로플루오로벤조일클로라이드를 서서히 적가한 다음 상온에서 24시간 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 아세토니트릴을 제거하고 1,500ml의 톨루엔 및 1,500ml의 2N-염산수용액을 주입하여 맹렬히 교반 후 2N-수산화나트륨수용액으로 중화한 다음 유기층을 분리하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거한 후 잔사를 헵탄으로 결정화하여 미황색의 에틸 2,3,4,5-테트라플루오로벤조일아세테이트 256.3g(94%)을 얻었다.357.4 g (2.1 mole) diethylmalonate potassium salt, 238.1 g (2.5 mole) magnesium chloride and 222.6 g (2.2 mole) triethylamine were suspended in 5,000 ml of acetonitrile. After stirring for 2 hours, 212.6 g (1 mole) of tetrafluorobenzoyl chloride was slowly added dropwise thereto, followed by vigorous stirring at room temperature for 24 hours. After the reaction was completed, the mixture was distilled under reduced pressure to remove acetonitrile, 1,500 ml of toluene and 1,500 ml of 2N hydrochloric acid solution were injected, stirred vigorously, neutralized with 2N-sodium hydroxide aqueous solution, and the organic layer was separated. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and the residue was crystallized with heptane to give 256.3 g (94%) of pale yellow ethyl 2,3,4,5-tetrafluorobenzoyl acetate.

융점: 63∼64℃ (dec.)Melting Point: 63 ~ 64 ℃ (dec.)

IR: υmax(cm-1): 1,735, 1,644, 1,615IR: υ max (cm -1 ): 1,735, 1,644, 1,615

H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):

1.31 (3H, m, -OCH2CH3), [3.96(d), 5.84(s), 12.71(s)] (2H, -CH2-),1.31 (3H, m, -OCH 2 CH 3 ), [3.96 (d), 5.84 (s), 12.71 (s)] (2H, -CH 2- ),

4.26 (2H, m, -OCH2CH3), 7.56 (1H, 방향성 H)4.26 (2H, m, -OCH 2 CH 3 ), 7.56 (1H, aromatic H)

실시예 3: 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트의 제조Example 3: Preparation of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate

264.2g(1mole)의 에틸 2,3,4,5-테트라플루오로벤조일아세테이트, 150.3g (1.5mole)의 4-메틸-피페라진 및 84.01g(1.5mole)의 중탄산나트륨을 2,000ml의 아세토니트릴에 혼탁시킨 용액을 90℃까지 가열하여 3시간 동안 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 아세트니트릴을 제거하고 1,000ml의 물 및 1,000ml의 클로로포름을 주입하여 맹렬히 교반 후 클로로포름층을 분리한 다음 동량의 물로 세척하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거한 후 잔사를 헥산으로 결정화하여 미황색의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트 316.8g(92%)을 얻었다.2,000 ml of acetonitrile in 264.2 g (1 mole) ethyl 2,3,4,5-tetrafluorobenzoyl acetate, 150.3 g (1.5 mole) 4-methyl-piperazine and 84.01 g (1.5 mole) sodium bicarbonate The solution that was clouded on was heated to 90 ° C. and vigorously stirred for 3 hours. After completion of the reaction, distillation under reduced pressure was carried out to remove acetonitrile, 1,000 ml of water and 1,000 ml of chloroform were injected thereto, followed by vigorous stirring to separate the chloroform layer, followed by washing with the same amount of water. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and the residue was crystallized from hexane to give a slightly yellow ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate. 316.8 g (92%) were obtained.

융점: 60∼61℃ (dec.)Melting Point: 60 ~ 61 ℃ (dec.)

IR: υmax(cm-1) : 1,746, 1,673, 1,620IR: υ max (cm -1 ): 1,746, 1,673, 1,620

H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):

1.27 and 1.33 (3H, m, -OCH2CH3), 2.34 (3H, s, =NCH3),1.27 and 1.33 (3H, m, -OCH 2 CH 3 ), 2.34 (3H, s, = NCH 3 ),

2.49∼2.57 (4H, m, 피페라진 H), 3.32∼3.44 (4H, m, 피페라진 H),2.49 to 2.57 (4H, m, piperazine H), 3.32 to 3.44 (4H, m, piperazine H),

[3.91(d), 5.78(s), 12.64(s)] (2H, -CH2-),[3.91 (d), 5.78 (s), 12.64 (s)] (2H, -CH 2- ),

4.22 and 4.26 (2H, each q, -OCH2CH3), 7.29∼7.36 (1H, 방향성 H)4.22 and 4.26 (2H, each q, -OCH 2 CH 3 ), 7.29-7.36 (1H, aromatic H)

실시예 4: 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일아크릴레이트의 제조Example 4: Preparation of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoylacrylate

344.3g(1mole)의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 296.4g(2mole)의 트리에틸올소포르메이트를 2,000ml의 툴루엔에 녹인 용액을 110℃까지 가열하여 24시간 동안 교반시켰다. 반응이 완결되면 1,000ml의 물을 가하여 맹렬히 교반 후 톨루엔층을 분리하고, 다시 동량의 물로 세척하였다. 이 반응혼합액을 황산마그네슘으로 건조하고 감압증류하여 용매를 제거하여 323.5g(99%)의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일아크릴레이트를 얻었다.2,000 ml of toluene in 344.3 g (1 mole) of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate and 296.4 g (2 mole) of triethylolsoformate The solution dissolved in was heated to 110 ° C. and stirred for 24 hours. After the reaction was completed, 1,000 ml of water was added thereto, and vigorously stirred, the toluene layer was separated, and washed with the same amount of water again. The reaction mixture was dried over magnesium sulfate, distilled under reduced pressure to remove the solvent, and 323.5 g (99%) of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) ] Benzoyl acrylate was obtained.

IR: υmax(cm-1): 1692, 1666, 1624, 1593IR: υ max (cm -1 ): 1692, 1666, 1624, 1593

H1NMR(CDCl3, 300MHz) (ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):

0.92 및 1.26(6H, 각각 t, -CO2CH2CH3, 및 CHOCH2CH3),0.92 and 1.26 (6H, t, —CO 2 CH 2 CH 3 , and CHOCH 2 CH 3, respectively ),

2.41(3H, s, -NCH3), 2.28~2.43(4H, m, 피페라진 H),2.41 (3H, s, -NCH 3 ), 2.28-2.43 (4H, m, piperazine H),

3.52~3.70(4H, m, 피페라진 H),3.52-3.70 (4H, m, piperazine H),

4.15 및 4.49(4H, 각각 q, -CO2CH2CH3, 및 =CHOCH2CH3),4.15 and 4.49 (4H, q, -CO 2 CH 2 CH 3 , and = CHOCH 2 CH 3, respectively ),

6.74~6.85(1H, m, 방향성 H),6.74-6.85 (1H, m, Directional H),

8.21 및 8.32(1H, 각각 d, =CHO-)8.21 and 8.32 (1H, d, = CHO- respectively)

실시예 5: 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)] 벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트의 제조Example 5: Ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy-2-ylamino Production of acrylate

344.3g(1mole)의 에틸 2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)벤조일 아세테이트와 296.4g(2mole)의 트리에틸올소포르메이트를 2,000ml의 톨루엔에 녹인 용액을 110℃까지 가열하여 24시간 동안 교반하고 톨루엔을 감압증류하여 제거시킨 후 2,000ml의 에탄올에 다시 녹였다. 여기에 112.7g(1.5mole)의 (S)-(+)-2-아미노-1-프로판올을 서서히 적가한 다음 상온에서 3시간 격렬하게 교반시켰다. 반응이 완결되면 감압증류하여 에탄올을 제거시켜 420.8g(98%)의 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트를 얻었다.344.3 g (1 mole) of ethyl 2,3,5-trifluoro-4- (4-methyl-1-piperazinyl) benzoyl acetate and 296.4 g (2 mole) of triethylolsoformate in 2,000 ml of toluene The dissolved solution was heated to 110 ° C., stirred for 24 hours, toluene was distilled off under reduced pressure, and then dissolved in 2,000 ml of ethanol. 112.7 g (1.5 mole) of (S)-(+)-2-amino-1-propanol was slowly added dropwise thereto, followed by vigorous stirring at room temperature for 3 hours. After completion of the reaction, the reaction mixture was distilled under reduced pressure to remove ethanol, and 420.8 g (98%) of ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 ( S)-(1-hydroxypropy-2-ylamino) acrylate was obtained.

IR: υmax(cm-1) : 1,681, 1,668, 1,625IR: υ max (cm -1 ): 1,681, 1,668, 1,625

H1NMR (CDCl3, 300MHz)(ppm):H 1 NMR (CDCl 3 , 300 MHz) (ppm):

0.98 and 1.09 (3H, 각각 t, -OCH2CH3), 1.35 (3H, d, -NHCHCH3),0.98 and 1.09 (3H, t, -OCH 2 CH 3 ), 1.35 (3H, d, -NHCHCH 3 ),

1.80∼2.20 (1H, br, -OH), 2.35 (3H, s, =NCH3),1.80-2.20 (1H, br, -OH), 2.35 (3H, s, = NCH 3 ),

2.30∼2.65 (4H, m, 피페라진 H), 3.20∼3.50 (4H, m, 피페라진 H),2.30 to 2.65 (4H, m, piperazine H), 3.20 to 3.50 (4H, m, piperazine H),

3.40∼3.60 (3H, m, =NCHCH2O-), 4.03 and 4.07 (2H, 각각 q, -OCH2CH3),3.40 to 3.60 (3H, m, = NCHCH 2 O-), 4.03 and 4.07 (2H, q and -OCH 2 CH 3 ),

6.80∼6.90 (1H, m, 방향성 H), 8.15 and 8.20 (1H, 각각 d, =CHN=),6.80 to 6.70 (1H, m, aromatic H), 8.15 and 8.20 (1H, d, = CHN =),

9.20∼9.70 and 10.50∼11.00 (1H, 각각 br, =NH)9.20-9.70 and 10.50-11.00 (1H, respectively br, = NH)

[α]D= -68.3° (c=0.12, CHCl3)[α] D = -68.3 ° (c = 0.12, CHCl 3 )

본 발명의 제조방법으로 제조된 상기 에틸 2-[2,3,5-트리플루오로-4-(4-메틸-1-피페라지닐)]벤조일-3(S)-(1-히드록시프로피-2-닐아미노)아크릴레이트는 항균제로 유용한 약제인 레보플록사신의 제조시 중간체로 유용하게 사용할 수 있다.Ethyl 2- [2,3,5-trifluoro-4- (4-methyl-1-piperazinyl)] benzoyl-3 (S)-(1-hydroxypropy) prepared by the preparation method of the present invention. 2-Nylamino) acrylate can be usefully used as an intermediate in the preparation of levofloxacin, a drug useful as an antibacterial agent.

Claims (9)

하기 화학식 4의 화합물을 하기 화학식 5의 화합물과 극성용매하에서 반응시켜 하기 화학식 1의 화합물을 제조하는 것을 특징으로 하는 방법.A method of preparing a compound of formula 1 by reacting a compound of formula 4 with a compound of formula 5 제1항에 있어서, 극성용매가 디메틸술폭시드, 디메틸포름아미드, 디메틸아세트아미드, 아세토니트릴, 물 및 에탄올성 용매로 이루어진 군으로부터 선택된 용매 또는 이들중 2종 이상을 혼합한 혼합용매인 것을 특징으로 하는 방법The method of claim 1, wherein the polar solvent is a solvent selected from the group consisting of dimethyl sulfoxide, dimethylformamide, dimethylacetamide, acetonitrile, water and ethanol solvent, or a mixed solvent of two or more thereof. How to 제1항에 있어서, 반응온도가 0~100℃인 것을 특징으로 하는 제조방법.The method according to claim 1, wherein the reaction temperature is 0 to 100 ° C. 제1항에 있어서, 화학식 4의 화합물은 하기 화학식 2의 화합물을 하기 화학식 3의 화합물과 비극성용매하에 반응시켜 얻는 것을 특징으로 하는 제조방법.The method of claim 1, wherein the compound of formula 4 is obtained by reacting a compound of formula 2 with a compound of formula 3 in a nonpolar solvent. 제4항에 있어서, 비극성용매가 톨루엔, 벤젠 및 헥산으로 이루어진 군으로부터 선택된 용매 또는 이들중 2종 이상을 혼합한 혼합용매인 것을 특징으로 하는 방법The method according to claim 4, wherein the nonpolar solvent is a solvent selected from the group consisting of toluene, benzene and hexane, or a mixed solvent in which two or more thereof are mixed. 제4항에 있어서, 반응온도가 20~200℃인 것을 특징으로 하는 제조방법.The production method according to claim 4, wherein the reaction temperature is 20 to 200 ° C. 제1항에 있어서, 화학식 5의 화합물이 하기 화학식 10의 화합물과 환원제로부터 반응시켜 얻어지는 것을 특징으로 하는 방법.The method of claim 1, wherein the compound of formula 5 is obtained by reacting the compound of formula 10 with a reducing agent. 제7항에 있어서, 환원제가 수소화알루미늄리튬, 삼플루오르화붕소, 라니 니켈 또는 수소화붕소나트륨인 것을 특징으로 하는 방법.8. The method of claim 7, wherein the reducing agent is lithium aluminum hydride, boron trifluoride, Raney nickel or sodium borohydride. 하기 화학식 1의 화합물.A compound of formula 1
KR10-1999-0034793A 1999-08-21 1999-08-21 Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof KR100494881B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-1999-0034793A KR100494881B1 (en) 1999-08-21 1999-08-21 Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1999-0034793A KR100494881B1 (en) 1999-08-21 1999-08-21 Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof

Publications (2)

Publication Number Publication Date
KR20010018722A true KR20010018722A (en) 2001-03-15
KR100494881B1 KR100494881B1 (en) 2005-06-14

Family

ID=19608177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-0034793A KR100494881B1 (en) 1999-08-21 1999-08-21 Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)]benzoyl-3(S)-(1-hydroxyprop-2-ylamino)acrylate and a process for preparing thereof

Country Status (1)

Country Link
KR (1) KR100494881B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170025811A (en) 2015-08-31 2017-03-08 동양알코아 주식회사 aluminium grating

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215591A (en) * 1986-03-14 1987-09-22 Dainippon Pharmaceut Co Ltd Production of pyridobenzoxazine derivative and intermediate therefor
KR920002192B1 (en) * 1988-06-02 1992-03-19 죠오 호꾸 고교 가부시기가이샤 Manipulaten for executing building works
KR920012087A (en) * 1990-12-27 1992-07-25 하기주 Method for preparing benzoxazine derivatives
KR960009997B1 (en) * 1992-08-25 1996-07-25 금성일렉트론 주식회사 Semiconductor memory cell and manufacturing method thereof
KR100248370B1 (en) * 1997-12-04 2000-03-15 이종배 Preparation of intermediate of (-)-3(s)-methylpyrido benzoxizine derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170025811A (en) 2015-08-31 2017-03-08 동양알코아 주식회사 aluminium grating

Also Published As

Publication number Publication date
KR100494881B1 (en) 2005-06-14

Similar Documents

Publication Publication Date Title
KR840002141B1 (en) Process for preparing benzoxazine derivatives
KR950011396B1 (en) Intermediate compound for preparing 4-oxoquinoline-3-carboxylic acid derivatives
US4777253A (en) Process for preparation of racemate and optically active ofloxacin and related derivatives
EP3380464A1 (en) Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors
FR2598709A1 (en) QUINOLINE-CARBOXYLIC ACID DERIVATIVES
US5521310A (en) Process to obtain benzoxazines to be used for the synthesis of ofloxazine, levofloxazine and derivatives
KR100309871B1 (en) Process for Preparing (-)Pyridobenzoxazine Carboxylic Acid Derivatives
JPH0692371B2 (en) Novel heterocyclic derivative, method for producing the same, and method for producing a medicine containing these and particularly useful as an aldose reductase inhibitor
KR100251522B1 (en) Pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof
KR20010018722A (en) Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate and a process for preparing thereof
US4826985A (en) Intermediates for preparation of racemate and optically active ofloxacin and related derivatives
KR100248370B1 (en) Preparation of intermediate of (-)-3(s)-methylpyrido benzoxizine derivative
KR960004825B1 (en) Novel quinolone compounds and method of preparing them (ñ�)
EP0675880B1 (en) Quinoline disulfides as intermediates
KR100355756B1 (en) Method for manufacturing a S-ofloxacin
KR100334462B1 (en) A process for producing ethyl 2-(2,3,4,5-tetrafluorobenzoyl)-3(S)-(1-hydroxyprop-2-ylamino)acrylate
KR100494880B1 (en) A process for preparing Ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate
JPH04270272A (en) Production of aminoalkylmorpholine derivative
KR100494882B1 (en) A process for preparing (-)-9-Fluoro-2,3-dihydro-3(S)-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
KR100310786B1 (en) Process for Preparing Optically Active Quinolone Carboxylic Acid Derivatives
HU214955B (en) Process for producing fluoro-quinoline carboxylic-3-acid derivatives
KR100440192B1 (en) Method of preparing optical active quinolonecarboxylic acid derivatives
KR970000950B1 (en) Benzoheterocyclic compounds and their preparing method
HU204256B (en) Process for producing quinoline-2,5-dions and pharmaceutical compositions containing them
KR20010019386A (en) A process for preparing (-)-9,10-Difluoro-2,3-dihydro-3(S)-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101224

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20111228

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20150106

Year of fee payment: 13